Shattuck Labs (STTK)
NASDAQ:STTK
STTK Stock Chart & Stats
$6.37
>-$0.01(-0.39%)
At close: 4:00 PM EST
$6.37
>-$0.01(-0.39%)
Day’s Range― - ―
52-Week Range$0.69 - $6.59
Previous CloseN/A
Volume43.14K
Average Volume (3M)611.52K
Market Cap
$455.86M
Enterprise Value$247.75M
Total Cash (Recent Filing)$54.19M
Total Debt (Recent Filing)$1.58M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
May 13, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding71,564,220
10 Day Avg. Volume648,995
30 Day Avg. Volume611,519
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.08
Price to Sales (P/S)253.99
P/FCF Ratio-6.36
Enterprise Value/Market Cap0.54
Enterprise Value/Revenue247.75
Enterprise Value/Gross Profit-139.89
Enterprise Value/Ebitda-5.33
Forecast
1Y Price Target
$10.00Price Target Upside56.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DataPositive Phase 1 readout showing durable receptor occupancy, clean safety, and low immunogenicity would materially de-risk development and prompt upward reappraisal of the company's clinical potential.
Financing And Development RunwayA strengthened balance sheet after recent financing enables advancement into a Phase 2 Crohn's disease study upon favorable early data and reduces near-term funding risk.
Mechanism Of ActionDR3-targeting design of SL-325 could deliver a stronger and more durable reduction in intestinal inflammation than TL1A blockade, supporting potential clinical differentiation versus existing therapies.
Bears Say
Development And Regulatory RiskClinical, regulatory, and commercial uncertainties could delay development or limit market opportunity, keeping the stock outcome-dependent and sensitive to trial or approval setbacks.
Immunogenicity RiskPrior anti-TL1A programs induced anti-drug antibodies that lowered drug exposure and efficacy, creating a meaningful immunogenicity risk that could blunt SL-325's clinical benefit.
Valuation And Financial RelianceReported operating losses mean company valuation depends heavily on future clinical success, exposing investors to funding pressure and potential dilution if trials fail to meet expectations.
Shattuck Labs News
STTK FAQ
What was Shattuck Labs’s price range in the past 12 months?
Shattuck Labs lowest stock price was $0.69 and its highest was $6.59 in the past 12 months.
What is Shattuck Labs’s market cap?
Shattuck Labs’s market cap is $455.86M.
When is Shattuck Labs’s upcoming earnings report date?
Shattuck Labs’s upcoming earnings report date is May 13, 2026 which is in 46 days.
How were Shattuck Labs’s earnings last quarter?
Shattuck Labs released its earnings results on Mar 05, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.136 by $0.016.
Is Shattuck Labs overvalued?
According to Wall Street analysts Shattuck Labs’s price is currently Undervalued.
Does Shattuck Labs pay dividends?
Shattuck Labs does not currently pay dividends.
What is Shattuck Labs’s EPS estimate?
Shattuck Labs’s EPS estimate is -0.15.
How many shares outstanding does Shattuck Labs have?
Shattuck Labs has 71,564,220 shares outstanding.
What happened to Shattuck Labs’s price movement after its last earnings report?
Shattuck Labs reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.136. Following the earnings report the stock price went up 7.822%.
Which hedge fund is a major shareholder of Shattuck Labs?
Currently, no hedge funds are holding shares in STTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shattuck Labs Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (56.99% Upside)
$10.00 (56.99% Upside)
Blogger Sentiment
Bullish
STTK Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 22.7%
Last 30 Days ▲ 22.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
393.54%
12-Months-Change
Fundamentals
Return on Equity
-65.03%
Trailing 12-Months
Asset Growth
-1.32%
Trailing 12-Months
Company Description
Shattuck Labs
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
STTK Stock 12 Month Forecast
Average Price Target
$10.00
▲(56.99% Upside)
Technical Analysis
PolyPid
―
Coeptis Therapeutics Holdings
―
―
Xilio Therapeutics
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
14.50% Insiders
6.19% Mutual Funds
40.37% Other Institutional Investors
35.65% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---